PathAI partners with Roche for AI tech

By staff writers

October 15, 2021 -- PathAI and Roche are partnering to develop and distribute PathAI's artificial intelligence (AI)-powered technology through Roche's uPath enterprise software.

The companies said the partnership allows for broad access to digital pathology diagnostics to support clinical research and companion diagnostic programs globally.

The collaboration will initially involve distributing algorithms developed by PathAI for research use only through Navify Digital Pathology, the cloud version of Roche's uPath enterprise software. The companies will focus on immuno-oncology in multiple cancer types.

The alliance will also support pharmaceutical partners with end-to-end software for companion diagnostic development using Roche's diagnostic assays and pathology lab solutions with imaging tools from PathAI in addition to the AI tools already provided by Roche.

Prenosis, Roche expand partnership to combat sepsis
Prenosis and Roche Diagnostics will expand their existing partnership with a $6 million infusion to improve and expedite the clinical identification...
PathAI, Summit Clinical partner for NASH trial services
PathAI recently entered a partnership with Summit Clinical Research that will launch a clinical trial services solution for developers of drugs to treat...
PathAI buys Poplar Healthcare
Pathology artificial intelligence software developer PathAI has purchased Poplar, the management service organization of Poplar Healthcare, an anatomic...
Roche announces FDA approval for COVID-19 test
Roche announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization for its Cobas SARS-CoV-2 nucleic acid test....
Venture capital funding for digital pathology tops $860M
While 2014-2017 reflected a relatively quiet period for investment in digital pathology, over the last three years there has been a significant uptick...

Copyright © 2021

Last Updated ka 10/15/2021 11:48:19 AM